When was Gate Bioscience founded?

Gate Bioscience was founded in 2018 and raised its 1st funding round 5 years after it was founded.

Where is Gate Bioscience located?

Gate Bioscience is headquartered in Brisbane, United States.

Who is the current CEO of Gate Bioscience?

Jordi Mata-Fink of Gate Bioscience. They have also founded 1 company.

How many employees does Gate Bioscience have?

As of Aug 31, 2026, the latest employee count at Gate Bioscience is 41.

Is Gate Bioscience a funded company?

Gate Bioscience is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on Nov 01, 2023.

When was the latest funding round of Gate Bioscience?

Gate Bioscience's latest funding was a $***** Series A round on Nov 01, 2023, with participation from 4 investors.

Where does Gate Bioscience rank among its competitors?

Gate Bioscience ranks 49th amongst 548 active competitors, of which 200 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Sirnaomics, which secured $17.7M in Sep, 2025.

Who are the top competitors of Gate Bioscience?

Gate Bioscience's top competitors include Alnylam, Spark Therapeutics and Forge Biologics. Among them, Sirnaomics secured the most recent funding round in September, 2025.

Gate Bioscience - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of small molecule drugs for the treatment of intractable diseases. The therapeutics involves selectively blocking disease-causing proteins at their origin inside cells. It prevents the proteins from emerging and causing disease. The platform combines a library of molecular gates with secretion-focused assays and technologies. It aims to enable precise and repeatable drug discovery.

Key Metrics

Founded Year

2018

Location

Brisbane, United States

Stage

Series A

Total Funding

$60M in 1 round

Latest Funding Round

Series A, Nov 01, 2023, $*****

Investors

Andreessen Horowitz & 3 more

Ranked

49^th among 548 active competitors

Employee Count

41 as on Aug 31, 2026

Similar Companies

Alnylam & 683 more

View Gate Bioscience's full profile

Gate Bioscience is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
GATE BIOSCIENCE CIN: 861631316 , United States, Active	Dec 31, 1999	-	33 (As on Dec 31, 2024)	-

Gate Bioscience has raised a total funding of $60M over 1 round. Its latest funding round was a Series A round on Nov 01, 2023 for $*****. 4 investors participated in its latest round. Gate Bioscience has 4 institutional investors.

Here is the list of recent funding rounds of Gate Bioscience:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 01, 2023	5459810	Series A	1172901	9923257	4513717	5278809

Access funding benchmarks and valuations. Sign up today!

View details of Gate Bioscience's funding rounds and investors

The founders of Gate Bioscience is Jordi Mata-Fink. Jordi Mata-Fink is the CEO of Gate Bioscience.

Here are the details of Gate Bioscience's key team members:

Jordi Mata-Fink: Co-Founder & CEO of Gate Bioscience.

View details of Gate Bioscience's Founder profiles and Board Members

Gate Bioscience's employee count trend

Gate Bioscience has 41 employees as of Aug 26. Here is Gate Bioscience's employee count trend over the years:

Employee count trend for Gate Bioscience

Uncover Gate Bioscience's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Gate Bioscience include Alnylam, Spark Therapeutics and Forge Biologics. Here is the list of Top 10 competitors of Gate Bioscience, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 13 others	80/100
2nd	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
3rd	Forge Biologics 2020, Columbus (United States), Acquired	Developer of gene therapeutic solutions for treating multiple diseases	$330M	RA Capital Management, Aisling Capital & 7 others	71/100
4th	Insitro 2018, San Francisco (United States), Series C	Developer of machine learning platform for drug discovery and development	$643M	Andreessen Horowitz, Foresite Capital & 18 others	70/100
5th	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, Playground Global & 19 others	69/100
6th	Passage Bio 2017, Philadelphia (United States), Public	Developer of gene therapies for CNS rare diseases	$226M	Access Biotechnology, Orbimed & 10 others	69/100
7th	Ultragenyx 2010, Novato (United States), Acquired	Developer of therapeutics for the treatment of rare and ultra-rare metabolic diseases	$135M	F-Prime Capital, Adage Capital Management ... & 10 others	69/100
8th	ElevateBio 2018, Cambridge (United States), Series D	Provider of transnational research for portfolio of cell and gene therapy	$1.25B	Matrix Capital Management, Invus & 16 others	68/100
9th	Krystal Biotech 2015, Pittsburgh (United States), Public	Developer of genetic medicines to treat rare diseases	$11.3M	Frazier Life Sciences, Danforth Advisors & 2 others	67/100
10th	Sirnaomics 2007, Gaithersburg (United States), Public	Developer of RNA based therapeutics for the treatment of cancer and fibrosis disease	$267M	Rotating Boulder Fund, Yuexiu Group & 16 others	67/100
49th	Gate Bioscience 2018, Brisbane (United States), Series A	Provider of small molecule modality development services for treatment of intractable diseases	$60M	Versant Ventures, Arch Venture Partners & 2 others	59/100